Consun Pharmaceutical Group Limited C1P.F Stock
Consun Pharmaceutical Group Limited Price Chart
Consun Pharmaceutical Group Limited C1P.F Financial and Trading Overview
Consun Pharmaceutical Group Limited stock price | 0.64 EUR |
Previous Close | 0.59 EUR |
Open | 0.56 EUR |
Bid | 0.55 EUR x N/A |
Ask | 0.61 EUR x N/A |
Day's Range | 0.56 - 0.56 EUR |
52 Week Range | 0.34 - 0.7 EUR |
Volume | 150 EUR |
Avg. Volume | 258 EUR |
Market Cap | 470.54M EUR |
Beta (5Y Monthly) | 0.743678 |
PE Ratio (TTM) | 5.090909 |
EPS (TTM) | 0.13 EUR |
Forward Dividend & Yield | 0.04 (6.46%) |
Ex-Dividend Date | June 8, 2023 |
1y Target Est | N/A |
C1P.F Valuation Measures
Enterprise Value | -1851688448 EUR |
Trailing P/E | 5.090909 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.20111723 |
Price/Book (mrq) | 0.14038606 |
Enterprise Value/Revenue | -0.791 |
Enterprise Value/EBITDA | -2.356 |
Trading Information
Consun Pharmaceutical Group Limited Stock Price History
Beta (5Y Monthly) | 0.743678 |
52-Week Change | 17.02% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.7 EUR |
52 Week Low | 0.34 EUR |
50-Day Moving Average | 0.56 EUR |
200-Day Moving Average | 0.47 EUR |
C1P.F Share Statistics
Avg. Volume (3 month) | 258 EUR |
Avg. Daily Volume (10-Days) | 1.34K EUR |
Shares Outstanding | 806.98M |
Float | 321.42M |
Short Ratio | N/A |
% Held by Insiders | 58.05% |
% Held by Institutions | 7.76% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0.265 |
Trailing Annual Dividend Yield | 44.91% |
5 Year Average Dividend Yield | 569.00% |
Payout Ratio | 0.1974 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 29.18% |
Operating Margin (ttm) | 30.57% |
Gross Margin | 75.34% |
EBITDA Margin | 33.58% |
Management Effectiveness
Return on Assets (ttm) | 9.66% |
Return on Equity (ttm) | 21.53% |
Income Statement
Revenue (ttm) | 2.34B EUR |
Revenue Per Share (ttm) | 2.96 EUR |
Quarterly Revenue Growth (yoy) | 16.19% |
Gross Profit (ttm) | N/A |
EBITDA | 785.89M EUR |
Net Income Avi to Common (ttm) | 682.91M EUR |
Diluted EPS (ttm) | 0.11 |
Quarterly Earnings Growth (yoy) | 13.70% |
Balance Sheet
Total Cash (mrq) | 3.04B EUR |
Total Cash Per Share (mrq) | 3.86 EUR |
Total Debt (mrq) | 460.18M EUR |
Total Debt/Equity (mrq) | 13.38 EUR |
Current Ratio (mrq) | 2.682 |
Book Value Per Share (mrq) | 3.989 |
Cash Flow Statement
Operating Cash Flow (ttm) | 947.68M EUR |
Levered Free Cash Flow (ttm) | 650.74M EUR |
Profile of Consun Pharmaceutical Group Limited
Country | Germany |
State | N/A |
City | Guangzhou |
Address | 71, Dongpeng Avenue |
ZIP | N/A |
Phone | 86 20 8226 4529 |
Website | https://www.chinaconsun.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 3009 |
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. Consun Pharmaceutical Group Limited was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.
Q&A For Consun Pharmaceutical Group Limited Stock
What is a current C1P.F stock price?
Consun Pharmaceutical Group Limited C1P.F stock price today per share is 0.64 EUR.
How to purchase Consun Pharmaceutical Group Limited stock?
You can buy C1P.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Consun Pharmaceutical Group Limited?
The stock symbol or ticker of Consun Pharmaceutical Group Limited is C1P.F.
Which industry does the Consun Pharmaceutical Group Limited company belong to?
The Consun Pharmaceutical Group Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Consun Pharmaceutical Group Limited have in circulation?
The max supply of Consun Pharmaceutical Group Limited shares is 864.32M.
What is Consun Pharmaceutical Group Limited Price to Earnings Ratio (PE Ratio)?
Consun Pharmaceutical Group Limited PE Ratio is 4.92307700 now.
What was Consun Pharmaceutical Group Limited earnings per share over the trailing 12 months (TTM)?
Consun Pharmaceutical Group Limited EPS is 0.13 EUR over the trailing 12 months.
Which sector does the Consun Pharmaceutical Group Limited company belong to?
The Consun Pharmaceutical Group Limited sector is Healthcare.